Download PDF
Dtsch Med Wochenschr 2009; 134(25/26): 1361-1366
DOI: 10.1055/s-0029-1225292
Klinischer Fortschritt | Commentary

© Georg Thieme Verlag KG Stuttgart · New York

Endokrinologie 2009

Endocrinology 2009B. Harbeck1 , H. Mönig1 , H. Lehnert1
  • 1Medizinische Klinik I – Endokrinologie, Universitätsklinikum Schleswig Holstein, Campus Lübeck
Further Information

Publication History

Publication Date:
10 June 2009 (online)

Also available at
    Permissions and Reprints

See also:

Glukokortikoidinduzierte Osteoporose (GIO)Geburtshilfe Frauenheilkd 2009; 69(12): 1104-1106
DOI: 10.1055/s-0029-1240645

Was ist neu?

  • Glukokortikoid-induzierte Osteoporose: Zoledronsäure zur Prävention und Therapie mindestens ebenso wirksam wie Risedronat; Teriparatide führt im Vergleich zu Alendronat zu einer stärkeren Zunahme der lumbalen Knochendichte.

  • Gastrointestinale Tumoren: Octreotid als Depot-Präparat beim hochdifferenzierten neuroendokrinen Karzinom des „Midgut” antiproliferativ wirksam; Everolimus in Kombination mit Octreotid LAR bei fortgeschrittenen niedrig- und mittelgradig differenzierten NET effektiv.

  • Primärer Hyperparathyreoidismus: Cinacalcet als erstes Kalzimimetikum für diese Indikation zugelassen.

  • Nebennierenrindenkarzinom: Vorschlag einer überarbeitete Klassifikation; die konservativen Therapiemöglichkeiten sind nach wie vor unbefriedigend; neue Ansätze werden derzeit in Studien untersucht.

Literatur

  • 1 Arnold R, Rinke A, Klose K J. et al . Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial.  Clin Gastroenterol Hepatol. 2005;  3 761-771
    Google Scholar
  • 2 Barlaskar F M, Spalding A C, Heaton J H. et al . Preclinical targeting of the type 1 insulin-like growth factor receptor in adrenocortical carcinoma.  J Clin Endocrinol Metab. 2009;  94 204-212
    Google Scholar
  • 3 Baudin E, Pellegriti G, Bonnay M. et al . Impact of monitoring plasma 1,1-dichlorodiphenildichlorethane (o,p’DDD) levels on the treatment of patients with adrenocortical carcinoma.  Cancer. 2001;  92 1385-1392
    Google Scholar
  • 4 Berruti A, Terzolo M, Pia A. et al . Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.  Cancer. 1998;  83 2194-2200
    Google Scholar
  • 5 Bilezikian J P, Potts J T, Fuleihan G. et al . Summary statement from a workshop on asymptomatic primary hyperparathyreoidism: a perspective for the 21st century.  J Clin Endocrinol Metab. 2002;  87 5353-5361
    Google Scholar
  • 6 Chow C C, Chan W B, Li J K. et al . Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism.  J Clin Endocrinol Metab. 2003;  88 581-587
    Google Scholar
  • 7 DeLellis R A, Lloyd R V, Heitz P U. et al .Pathology and genetics of tumours of endocrine organs. Lyon, Frankreich; IARC 2004
    Google Scholar
  • 8 Doghman M, Cazareth J, Douguet D. et al . Inhibition of adrenocortical carcinoma cells proliferation by SF-1 inverse agonists.  J Clin Endocrinol Metab. 2009 Mar 24. Epub ahead of print; 
    Google Scholar
  • 9 Doghman M, Cazareth J, Lalli E. The T cell factor/beta-catenin antagonist PKF 115 – 584 inhibits proliferation of adrenocortical carcinoma cells.  J Clin Endocrinol Metab. 2008;  93 3222-3225
    Google Scholar
  • 10 Doghman M, Karpova T, Rodrigues G A. et al . Increased steroidogenic factor-1 dosage triggers adrenocortical cell proliferation and cancer.  Mol Endocrinol. 2007;  21 2968-2987
    Google Scholar
  • 11 Fastnacht M, Johanssen S, Quinkler M. et al . Limited prognostic value of the 2004 International Union against Cancer staging classification for adrenocortical carcinoma.  Cancer. 2009 published online 15.01.2009; 
    Google Scholar
  • 12 Grey A B, Stapleton J P, Evans M C, Reid I R. et al . Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparythyroidism. A randomized, controlled trial.  Ann Intern Med. 1996;  125 360-368
    Google Scholar
  • 13 Haak H R, Hermans J, van de Velde C J. et al . Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients.  Br J Cancer. 1994;  69 947-951
    Google Scholar
  • 14 Khan A, Grey A, Shoback D. Medical management of asymptomatic primary hyperthyroidism: Proceedings of the Third International Workshop.  J Clin Endocrinol Metab. 2009;  94 373-381
    Google Scholar
  • 15 Khan A A, Bilezikian J P, Kung A W, Schussheim D, Rubin M R, Shaikh A M, Silverberg S J, Standish T I, Syed Z, Syed Z A. et al . Alendronate in primary hyperparathyroidism: a double blind, randomized, placebo controlled trial.  J Clin Endocrinol Metab. 2004;  89 3319-3325
    Google Scholar
  • 16 Khan T S, Imam H, Juhlin C. Streptozocin and o. p. ’DDD in the treatment of adrencortical cancer patients: long term survival in its adjuvant use.  Ann Oncol. 2000;  11 1281-1287
    Google Scholar
  • 17 Kidd M, Drozdov I, Joseph R. et al . Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines.  Cancer. 2008;  113 690-700
    Google Scholar
  • 18 Kvols L K, Moertel C G, O’Connell M J. et al . Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.  N Engl J Med. 1986;  315 663-666
    Google Scholar
  • 19 Langdahl B L, Marin F, Shane E. et al . Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status.  Osteoporos Int. 2009;  , [Epub ahead of print] DOI: 10.1007/s00198–009–0917-y
    Google Scholar
  • 20 Lee J O, Lee K W, Kim C J. et al . Metastatic adrenocortical carcinoma treated with sunitinib: a case report.  Jpn J Clin Oncol. 2009;  39 183-185
    Google Scholar
  • 21 Leidig-Bruckner G, Hosch S, Dodidou P. et al . Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study.  Lancet. 2001;  357 342-347
    Google Scholar
  • 22 Nakamura M, Miki Y, Akahira J. et al . An analysis of potential surrogate markers of target-specific therapy in archival materials of adrenocortical carcinoma.  Endocr Pathol. 2009;  20 17-23
    Google Scholar
  • 23 Oberg K, Kvols L, Caplin M. et al . Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system.  Ann Oncol. 2004;  15 966-973
    Google Scholar
  • 24 Parker C R, Blackwell P J, Fairbairn K J. et al . Alendronate in the treatment of primary hyperparathyroid-related ostoporosis: a 2-year study.  J Clin Endocrinol Metab. 2002;  87 4482-4489
    Google Scholar
  • 25 Peacock M, Bilezikian J P, Klassen P S. et al . Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism.  J Clin Endocrinol Metab. 2005;  90 135-141
    Google Scholar
  • 26 Polat B, Fassnacht M, Pfreundner L. et al . Radiotherapy in adrenocortical carcinoma.  Cancer. 2009 Apr 28. Epub ahead of print; 
    Google Scholar
  • 27 Reid D M, Devogelaer J P, Saag K. et al; HORIZON investigators . Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.  Lancet. 2009;  373 1253-1263
    Google Scholar
  • 28 Rossini M, Gatti D, Isaia G. et al . Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.  J Bone Miner Res. 2001;  16 113-119
    Google Scholar
  • 29 Rubin M R, Lee K H, McMahon D J. et al . Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism.  J Clin Endocrinol Metab. 2003;  88 1174-1178
    Google Scholar
  • 30 Schmid A. Pasireotide (SOM230): development, mechanism of action and potential applications.  Mol Cell Endocrinol. 2008;  286 269-274
    Google Scholar
  • 31 Selby P L, Peacock M. Ethinyl estradiol and norethindrone in the treatment of primary hyperparathyroidism in postmenopausal women.  N Engl J Med. 1986;  314 1481-1485
    Google Scholar
  • 32 Shoback D M, Bilezikian J P, Turner S A. et al . The calcimimetic AMG 073 normalizes serum calcium in patients with primary hyperparathyroidism.  J Clin Endocrinol Metab. 2003;  88 5644-5649
    Google Scholar
  • 33 Solcia E, Klöppel G, Sobin L H. et al .Histological typing of endocrine tumours. 2nd Ed. WHO International Histological Classification of Tumours. Berlin; Springer 2000
    Google Scholar
  • 34 Steinmüller T, Kianmanesh R, Falconi M. et al, Consensus Conference participants . Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary.  Neuroendocrinology. 2008;  87 47-62
    Google Scholar
  • 35 Terzolo M, Angeli A, Fassnacht M. et al . Adjuvant mitotane treatment for adrenocortical carcinoma.  N Engl J Med. 2007;  356 2372-2380
    Google Scholar
  • 36 Terzolo M, Berruti A. Adjunctive treatment of adrenocortical carcinoma.  Curr Opin Endocrinol Diabetes Obes. 2008;  15 221-226
    Google Scholar
  • 37 Vestergaard P. Current pharmacological options for the management of primary hyperparathyroidism.  Drugs. 2006;  66 2189-2211
    Google Scholar
  • 38 Willenberg H S, Lehnert H. Grundlagen und Management der glukokortikoid-induzierten Osteoporose.  Internist. 2008;  49 1186-1196
    Google Scholar
  • 39 Yao J C, Phan A T, Chang D Z. et al . Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study.  J Clin Oncol. 2008;  26 4311-4318
    Google Scholar
  • 40 Zanchetta J R, Bogado C E. Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism.  J Bone Miner Res. 2001;  16 189-190
    Google Scholar

Prof. Dr. Heiner Mönig

Medizinische Klinik I – Endokrinologie, Universitätsklinikum Schleswig-Holstein, Campus Lübeck

Ratzeburger Allee 160

23538 Lübeck

Phone: 0451/500-2360

Fax: 0451/500-2938

Email: heiner.moenig@uk-sh.de

      >